Immunexpress

Immunexpress is a privately-held molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis.

[Immunexpress @Immunexpress]

Immunexpress is presenting at #SCCM 2026, showcasing data on SeptiCyte RAPID®, including strong correlation with blood culture–positive sepsis (91%) and results in ~1 hour.

Chicago | Booth #642
March 22–24

https://t.co/VHZkaPhQfQ

[Immunexpress @Immunexpress]

New publication in the European Journal of Haematology demonstrates that SeptiCyte RAPID® differentiates infection from sterile inflammation in bone marrow transplant patients with febrile neutropenia.

Read more here: https://t.co/v4HwocWxeQ

[Immunexpress @Immunexpress]

From the team at Immunexpress, wishing everyone a safe and happy Thanksgiving holiday!

[Immunexpress @Immunexpress]

The 9th Annual National Hospitalist Conference is just around the corner in Clearwater Beach, Florida from December 1-4! We hope to see you there.

If you are attending, visit our booth!

Learn more here: https://t.co/SIxTdHVp4V

#HospitalMedicine #MedicalEducation #PatientCare

[Immunexpress @Immunexpress]

Flu season is here, and the flu can sometimes lead to serious infections which can escalate into life-threatening complications such as #sepsis, a medical emergency. Know the warning signs of sepsis, as early recognition saves lives.

Learn more here:
https://t.co/QYjGDdGQ01

[Immunexpress @Immunexpress]

Two-thirds of #sepsis cases affect adults over 60 and can begin with an infection, a wound, or an invasive device like a feeding tube. Older adults face higher risk and every hour of delayed treatment increases the risk of death by 8%.

Learn more here:
https://t.co/3D5llFn79u

[Immunexpress @Immunexpress]

We are excited to share that our team will be attending the 9th Annual National Hospitalist Conference in Clearwater Beach from December 1-4!

If you are attending, visit our booth!

Learn more here: https://t.co/Umf3dVy9cq

#HospitalMedicine #MedicalEducation #PatientCare

[Immunexpress @Immunexpress]

The #GBD2021 study shows sepsis remaining a leading cause of death worldwide, responsible for 31.5% of deaths in 2021, highlighting an urgent need for infection prevention, early recognition, and chronic disease management.

Read the full publication: https://t.co/LrBqi6siYH

[Immunexpress @Immunexpress]

Early and accurate sepsis diagnosis must work for all patients, but the signs and responses to infection can vary widely. SeptiCyte® RAPID has been clinically validated across patient groups and in heterogeneous patient populations.

Learn more here:
https://t.co/jG7UjLZVP1

[Immunexpress @Immunexpress]

Increasing awareness about #sepsis, and sustained efforts to improve healthcare infrastructure and technologies available for sepsis diagnosis, such as SeptiCyte® RAPID, is driving the expansion of the sepsis diagnostics market.

Read more here:
https://t.co/JMZlitKGH6

[Immunexpress @Immunexpress]

Sepsis starts with an infection. But when the body’s response spirals out of control, it can become life-threatening within hours.

Learn more here: https://t.co/IJGquiNJZx

Early recognition and treatment are critical to survival.

#SepsisAwareness #PatientSafety

[Immunexpress @Immunexpress]

Early #sepsis recognition saves lives, especially among high-risk groups including diabetics.

SeptiCyte® RAPID has demonstrated effectiveness in quickly diagnosing #sepsis in hyperglycemic patients.

Read more here: https://t.co/vMOZeFcKkU

[Immunexpress @Immunexpress]

Fast and accurate diagnostics tools such as SeptiCyte® RAPID can help clinicians make better decisions and address the threat of antimicrobial resistance in #sepsis treatment.

Learn more here:
https://t.co/JYhvIayoLB

[Immunexpress @Immunexpress]

Immunexpress today announced publications of two articles in the @IJMS_MDPI and @JCriticalCare that demonstrated the clinical utility of SeptiCyte® RAPID for #sepsis diagnosis in critically ill surgical patients.

Read here:
https://t.co/6rtTg160pA & https://t.co/MvrZ14i0kv

[Immunexpress @Immunexpress]

SeptiCyte® RAPID uses a novel immune response signature to quickly differentiate sepsis from non-infectious systemic inflammation, and is the only FDA-cleared molecular lab-based test for sepsis.

Learn more here:
https://t.co/Eas0kuFxCq

#Diagnostics #MedicalTechnology

[Immunexpress @Immunexpress]

Sepsis progresses in hours, but commonly employed diagnostic tools take far too long to give a result.

To keep pace with this life-threatening condition, we developed SeptiCyte® RAPID, with actionable results ready in about an hour.

Learn more here:
https://t.co/Eas0kuFxCq

[Immunexpress @Immunexpress]

Sepsis often goes unrecognized until it is too late. Current diagnostic tools lag behind the speed at which #sepsis progresses, leaving doctors without the answers they urgently need.

Innovation in sepsis detection is an imperative for patients.

#SepsisAwareness #Diagnostics

[Immunexpress @Immunexpress]

The 2025 @SCCM Florida Chapter Annual Symposium was a great opportunity to connect with colleagues, learn from the latest innovation, and contribute to the important discussions shaping the future of critical care.

See you next year!

#CriticalCare #SCCM

[Immunexpress @Immunexpress]

We are excited to share that our team will be attending the 2025 @SCCM Florida Chapter Annual Symposium from October 3-4.

If you are attending, visit our booth!

Learn more here: https://t.co/sp5bdDh6Rj

#CriticalCare #SCCM

[Immunexpress @Immunexpress]

As Sepsis Awareness Month concludes, it is important to remember the toll of #sepsis. With more than 350,000 victims in the U.S. every year, sepsis takes a life very 90 seconds. Action is needed on better diagnostics and treatments.

Learn more here:
https://t.co/z2qB986Zbi